The results, published in JAMA Ophthalmology, showed that in confirmed eyesight progression was more prevalent and regression much less common. And if AMD was more severe in one eye then the risk of AMD and accelerated progression was considerably elevated in the fellow eye. The risk of transition up a known level was increased 4.9-fold for level one to two 2, 2.09-fold for level 2-3 3, 2.38-fold for level three to four 4 and 2.46-fold for transition from level 4 to 5. In comparison, less severe AMD in one eye was associated with a lesser incidence of AMD progression in the fellow attention, with odds ratios of 0.42 for transitioning from level 2-3 3 and 0.50 for transitioning from level three to four 4.‘As the treatment is not really a cure, it can increase survival by almost a year.’ Brain and nervous program cancers shall be diagnosed within an estimated 23, 000 Americans this whole year, killing more than 15,000, the FDA said, citing the U.S. National Tumor Institute. Glioblastoma multiforme accounts for some 15 % of brain tumors, in fact it is most diagnosed among people aged 45 to 70 often. Optune was first approved in 2011 to treat this kind of brain cancer once it got progressed despite chemotherapy. It should not be used without a doctor’s supervision, the company warned. Skin irritation may be the most common side-effect, and users have a slightly greater-than-average threat of neurologic effects also, including headaches or convulsions, the FDA said.